The VEGF pathway in cancer and disease

Responses, resistance, and the path forward

Mark W. Kieran, Raghu Kalluri, Yoon-Jae Cho

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago. Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate angiogenesis, their cellular targets, many of the pathways they signal, and inhibitors of the cytokines and receptors have been identified. Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and is believed to play a central role in the process of neovascularization, both in cancer as well as other inflammatory diseases. This article reviews the biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy.

Original languageEnglish (US)
Article numbera006593
JournalCold Spring Harbor Perspectives in Medicine
Volume2
Issue number12
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Disease Resistance
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Cytokine Receptors
Angiogenesis Inducing Agents
Toxicity
Signal Transduction
Neoplasms
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The VEGF pathway in cancer and disease : Responses, resistance, and the path forward. / Kieran, Mark W.; Kalluri, Raghu; Cho, Yoon-Jae.

In: Cold Spring Harbor Perspectives in Medicine, Vol. 2, No. 12, a006593, 01.01.2012.

Research output: Contribution to journalArticle

@article{b36bf84c28bc490988f565b50f419730,
title = "The VEGF pathway in cancer and disease: Responses, resistance, and the path forward",
abstract = "Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago. Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate angiogenesis, their cellular targets, many of the pathways they signal, and inhibitors of the cytokines and receptors have been identified. Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and is believed to play a central role in the process of neovascularization, both in cancer as well as other inflammatory diseases. This article reviews the biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy.",
author = "Kieran, {Mark W.} and Raghu Kalluri and Yoon-Jae Cho",
year = "2012",
month = "1",
day = "1",
doi = "10.1101/cshperspect.a006593",
language = "English (US)",
volume = "2",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "12",

}

TY - JOUR

T1 - The VEGF pathway in cancer and disease

T2 - Responses, resistance, and the path forward

AU - Kieran, Mark W.

AU - Kalluri, Raghu

AU - Cho, Yoon-Jae

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago. Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate angiogenesis, their cellular targets, many of the pathways they signal, and inhibitors of the cytokines and receptors have been identified. Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and is believed to play a central role in the process of neovascularization, both in cancer as well as other inflammatory diseases. This article reviews the biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy.

AB - Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago. Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate angiogenesis, their cellular targets, many of the pathways they signal, and inhibitors of the cytokines and receptors have been identified. Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and is believed to play a central role in the process of neovascularization, both in cancer as well as other inflammatory diseases. This article reviews the biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84877296919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877296919&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a006593

DO - 10.1101/cshperspect.a006593

M3 - Article

VL - 2

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 12

M1 - a006593

ER -